Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Although both structures offer liability protections, LLCs are best for tax flexibility and corporations are ideal for raising capital. Many, or all, of the products featured on this page are from ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...